ODTX

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company which develops medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system for patients suffering from autoimmune and inflammatory diseases. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains. The company was founded by Gary D. Glick, Melissa Merrick and David L. Pompliano in April 2021 and is headquartered in Boston, MA.